cosyntropin and Nephrotic-Syndrome

cosyntropin has been researched along with Nephrotic-Syndrome* in 3 studies

Reviews

1 review(s) available for cosyntropin and Nephrotic-Syndrome

ArticleYear
Leveraging melanocortin pathways to treat glomerular diseases.
    Advances in chronic kidney disease, 2014, Volume: 21, Issue:2

    The melanocortin system is a neuroimmunoendocrine hormone system that constitutes the fulcrum in the homeostatic control of a diverse array of physiological functions, including melanogenesis, inflammation, immunomodulation, adrenocortical steroidogenesis, hemodynamics, natriuresis, energy homeostasis, sexual function, and exocrine secretion. The kidney is a quintessential effector organ of the melanocortin hormone system with melanocortin receptors abundantly expressed by multiple kidney parenchymal cells, including podocytes, mesangial cells, glomerular endothelial cells, and renal tubular cells. Converging evidence unequivocally demonstrates that the melanocortin-based therapy using the melanocortin peptide adrenocorticotropic hormone (ACTH) is prominently effective in inducing remission of steroid-resistant nephrotic syndrome caused by various glomerular diseases, including membranous nephropathy, minimal change disease and focal segmental glomerulosclerosis, suggesting a steroidogenic-independent mechanism. Mechanistically, ACTH and other synthetic melanocortin analogues possess potent proteinuria-reducing and renoprotective activities that could be attributable to direct protection of glomerular cells and systemic immunomodulation. Thus, leveraging melanocortin signaling pathways using ACTH or novel synthetic melanocortin analogues represents a promising and pragmatic therapeutic strategy for glomerular diseases. This review article introduces the biophysiology of the melanocortin hormone system with an emphasis on the kidney as a target organ, discusses the existing data on melanocortin therapy for glomerular diseases, and elucidates the potential mechanisms of action.

    Topics: Adrenocorticotropic Hormone; alpha-MSH; Cosyntropin; Endothelial Cells; Glomerulonephritis; Glomerulonephritis, Membranous; Glomerulosclerosis, Focal Segmental; Hormones; Humans; Kidney; Kidney Glomerulus; Melanocortins; Mesangial Cells; Nephrosis, Lipoid; Nephrotic Syndrome; Podocytes; Receptors, Melanocortin; Signal Transduction

2014

Trials

1 trial(s) available for cosyntropin and Nephrotic-Syndrome

ArticleYear
Adrenocortical suppression increases the risk of relapse in nephrotic syndrome.
    Archives of disease in childhood, 2007, Volume: 92, Issue:7

    Children with nephrotic syndrome (NS) are usually treated with long-term low dose alternate day prednisolone with or without glucocorticoid sparing therapy, such as levamisole or ciclosporin, to maintain remission. The degree of hypothalamic-pituitary-adrenal axis (HPA) suppression with such therapeutic strategies has not been studied systematically. HPA suppression could cause a relapse or adrenal crisis.. To study the risks of HPA suppression, a modified low dose synacthen test (0.5 mug) was administered to 32 patients (22 male,10 female) with a mean age of 9.7 years (range 3.8-17.6 years) with NS receiving long-term alternate day prednisolone for over 12 months. Twelve patients received alternate day prednisolone, 11 alternate prednisolone+levamisole and nine alternate prednisolone+ciclosporin. All patients were followed up for 3 years and the relapse rate noted.. 20/32 (62.5%) patients had a peak serum cortisol concentration of <500 nmol/l, which suggested suboptimal cortisol secretion and possible HPA suppression. 10/12 children in the prednisolone group and 8/11 in the levamisole group had a suboptimal cortisol response compared with 2/9 in the ciclosporin group. During follow-up, the 20 children who had a suboptimal cortisol response had significantly more relapses (95 relapses) compared to the 12 children with a normal cortisol response who had 24 relapses (p = 0.01).. Children with NS receiving long-term alternate day prednisolone therapy are at risk of developing HPA suppression and should be evaluated using the modified synacthen test. Children with evidence of HPA suppression are at a greater risk of relapse.

    Topics: Adolescent; Child; Child, Preschool; Cosyntropin; Cyclosporine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Levamisole; Male; Nephrotic Syndrome; Pituitary-Adrenal System; Prednisolone; Recurrence

2007

Other Studies

1 other study(ies) available for cosyntropin and Nephrotic-Syndrome

ArticleYear
ACTH therapy in nephrotic syndrome induced by idiopathic membranous nephropathy.
    Clinical nephrology, 2004, Volume: 62, Issue:5

    Topics: Aged; Cosyntropin; Female; Glomerulonephritis, Membranous; Humans; Male; Middle Aged; Nephrotic Syndrome

2004